Martinez Maria de la Huerta - 16 Sep 2025 Form 3 Insider Report for Biofrontera Inc. (BFRI)

Role: Director, 10%+ Owner
Signature: /s/ Maria del Pilar de la Huerta Martinez
Issuer symbol: BFRI
Transactions as of: 16 Sep 2025
Transactions value $: $0
Form type: 3
Filing time: 25 Sep 2025, 15:23:21 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
de la Huerta Martinez Maria del Pilar	Director, 10%+ Owner	HEMMELRATHER WEG 201, LEVERKUSEN, GERMANY	/s/ Maria del Pilar de la Huerta Martinez	25 Sep 2025	0002084869

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BFRI	Common Stock						400K	16 Sep 2025	By Biofrontera AG	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BFRI	Series D Convertible Preferred Stock							16 Sep 2025	Common Stock	4.83M	$0.00	By Biofrontera AG	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares are held directly by Biofrontera AG. The Reporting Person may be deemed to beneficially own the shares owned by Biofrontera AG because of her position as the sole member of the management board of Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2	The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

Content

The reported shares are held directly by Biofrontera AG. The Reporting Person may be deemed to beneficially own the shares owned by Biofrontera AG because of her position as the sole member of the management board of Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

Remarks:

Biofrontera AG has entered into an agreement with the Issuer pursuant to which Biofrontera AG may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent Biofrontera AG on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation and the Reporting Person's position as the sole member of the management board of Biofrontera AG, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.